Part Width · Blood Work · CityLink Mall
Female pattern thinning is not the female version of male balding. It spreads diffusely across the crown while preserving the frontal hairline, and it is the one presentation that should never be treated before it has been investigated — because several correctable conditions produce exactly the same appearance.
The underlying process is the same miniaturisation seen in men — anagen shortens, each successive hair is finer, and coverage falls — but the geography is entirely different. In women the change is spread across the mid-frontal scalp and crown rather than concentrated at the temples and vertex, and the frontal hairline is characteristically retained as a preserved band a centimetre or two deep. That retained hairline is the single most useful clinical sign, and it is why women rarely recognise what is happening until a photograph taken from above surprises them.
Because the loss is diffuse, density falls a long way before the scalp becomes visible. A head of hair can lose a substantial proportion of its total mass and still look adequately covered from the front. What gives it away is the part — the same parting, combed the same way, gradually widens, and the ponytail thins at the elastic. Women describe the change in terms of behaviour rather than appearance: the hair no longer holds a style, the volume at the root has gone, the same clip now closes too easily.
The hormonal picture is also less clean than in men. Female pattern hair loss is not uniformly androgen-dependent, and many affected women have entirely normal androgen levels and no other endocrine feature whatsoever. Local follicular sensitivity, aromatase activity, which is higher in the female frontal scalp, and the fall in circulating oestrogen around menopause all contribute. This is why treatments developed against male androgen physiology do not translate directly, and why the evidence base in women is a different body of work.
What makes the diagnosis genuinely difficult is overlap. Iron deficiency, thyroid dysfunction, chronic telogen effluvium and postpartum shedding all produce diffuse thinning over the same territory, and they frequently coexist with genuine pattern loss rather than replacing it. A woman can have both, and treating only the pattern component in someone whose ferritin is low produces a disappointing twelve months and an unnecessary conclusion that nothing works.
Grading
Female pattern loss is staged by how far the central part has widened and how much scalp shows through the crown when the hair is parted and photographed from above. The stage is not simply a severity label — it determines whether the objective is recovery of density or preservation of what remains, and those are different conversations.
In a woman, thinning hair is a symptom until it has been investigated. Treating it as a diagnosis is how a correctable deficiency gets a year of laser instead of a blood test.
Assessment
Investigation is not a formality in female thinning — it changes management often enough that skipping it is indefensible. Full blood count, ferritin and iron studies, and thyroid function are the minimum, because iron deficiency and thyroid disease are both common in women, both produce diffuse hair loss, and both are correctable. Ferritin specifically, rather than haemoglobin alone: a woman can have a normal haemoglobin and depleted iron stores, and the hair follicle is among the first tissues to register that depletion.
Where there are clinical signs of androgen excess — irregular or absent periods, adult acne along the jaw, coarse hair in an androgen-dependent distribution — the workup extends to an androgen profile, because polycystic ovary syndrome and rarer endocrine causes need identifying before a cosmetic plan is built on top of them. Equally important is a medication and timeline review. Rapid weight loss, a new contraceptive, a recent pregnancy, a febrile illness or surgery four months earlier all point toward telogen effluvium rather than pattern loss, and the treatment for those two is not the same.
Only once that is settled does the plan get written. Medical therapy in women is prescribed differently from men and the options depend on childbearing plans, so that conversation happens early rather than as an afterthought. Non-pharmacological follicle stimulation and autologous micrografting have a role for women who cannot take systemic treatment or want to work alongside it. What none of them can do is compensate for an untreated deficiency sitting underneath.
Continue
Atelier Aesthetics · Owned by AYA
1 Raffles Link, #B1-28, CityLink Mall, Singapore 039393 · +65 8023 7170
Book a Consultation